<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>242265</rcn>
  <id>190129097</id>
  <acronym>CD20CARNAPT</acronym>
  <teaser>Elicera developed a universally compatible technology platform called iTANK (ImmunoTherapies Activated with NAP for efficient Killing) to enhance the efficacy of current and under development CAR-T cell therapies by inducing a dual mechanism-of-action in the treatment of...</teaser>
  <objective>Elicera developed a universally compatible technology platform called iTANK (ImmunoTherapies Activated with NAP for efficient Killing) to enhance the efficacy of current and under development CAR-T cell therapies by inducing a dual mechanism-of-action in the treatment of lymphomas and solid tumours. Elicera’s iTANK platform can circumvent major challenges of CAR-T cells in the treatment of solid tumours, such as antigen heterogenicity, local immunosuppression, and CAR T-cell exhaustion.  As such, the iTANK platform has a potential to revolutionise the landscape of the immuno-oncology

Our innovation arms CAR-T cells with NAP from H.pylori which induces a pro-inflammatory microenvironment and activates the patient’s own CD8+ killer T-cells against the whole repertoire of relevant tumour antigen targets. When tumour cells are killed, NAP-activated dendritic cells can take up tumour-associated antigens and prime killer T-cells against these antigens overcoming problems for CAR-T therapy.</objective>
  <title>iTANK: a nuniversal technology to boost the efficacy of CAR T cell therapies by inducing dual mode-of-actio</title>
  <totalCost>3604499</totalCost>
  <ecMaxContribution>2499999</ecMaxContribution>
  <startDate>2022-10-01</startDate>
  <endDate>2025-09-30</endDate>
  <ecSignatureDate>2022-09-26</ecSignatureDate>
  <duration>36</duration>
  <status>SIGNED</status>
  <keywords>dual anticancer action,genetic modification,T cells,immunomodulation,B-Cell lymphoma,NHL,CAR T-cell therapy</keywords>
  <identifiers>
    <grantDoi>10.3030/190129097</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-10-20 17:38:03</sourceUpdateDate>
  <contentCreationDate>2022-09-30 15:48:49</contentCreationDate>
  <contentUpdateDate>2025-11-26 10:54:35</contentUpdateDate>
  <lastUpdateDate>2025-11-26 10:54:37</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>438599</rcn>
        <id>438599-enhancing-immunotherapy-efficacy</id>
        <title>Enhancing immunotherapy efficacy</title>
        <contentUpdateDate>2023-03-06 16:12:51</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55635</rcn>
        <title>HORIZON-EIC-2022-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2022-ACCELERATOR-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55635</rcn>
        <title>HORIZON-EIC-2022-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2022-ACCELERATOR-01</identifier>
      </call>
      <organization netEcContribution="2499999" totalCost="3604499" source="corda" order="1" ecContribution="2499999" terminated="false" sme="true" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1978148</rcn>
        <id>890218568</id>
        <vatNumber>SE556966495501</vatNumber>
        <legalName>ELICERA THERAPEUTICS AB</legalName>
        <address>
          <street>BOX 5243</street>
          <city>GOTEBORG</city>
          <postalCode>402 24</postalCode>
          <country>SE</country>
          <geolocation>57.6487986,11.719643465644351</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Västra Götalands län</name>
              <rcn>473440450</rcn>
              <nutsCode>SE232</nutsCode>
              <parents>
                <region>
                  <name>Västsverige</name>
                  <rcn>473440488</rcn>
                  <nutsCode>SE23</nutsCode>
                  <parents>
                    <region>
                      <name>Södra Sverige</name>
                      <rcn>473442856</rcn>
                      <nutsCode>SE2</nutsCode>
                      <parents>
                        <region>
                          <name>Sweden</name>
                          <rcn>473598504</rcn>
                          <nutsCode>SE</nutsCode>
                          <euCode>SE</euCode>
                          <isoCode>SE</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Sweden</name>
              <rcn>473598504</rcn>
              <nutsCode>SE</nutsCode>
              <euCode>SE</euCode>
              <isoCode>SE</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>706909</rcn>
        <id>HORIZON_HORIZON-EIC-2022-ACCELERATOROPEN-01</id>
        <code>HORIZON-EIC-2022-ACCELERATOROPEN-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Accelerator Open</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456234</code>
              <title>Project financing</title>
              <displayCode>/Project financing</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43454386</code>
              <title>Market-creating innovation</title>
              <displayCode>/Market-creating innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450539</code>
              <title>Competitor analysis</title>
              <displayCode>/Competitor analysis</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450029</code>
              <title>Business model innovation</title>
              <displayCode>/Business model innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43451698</code>
              <title>Entrepreneurship</title>
              <displayCode>/Entrepreneurship</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453594</code>
              <title>Innovation support services</title>
              <displayCode>/Innovation support services</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43457773</code>
              <title>Spin-off companies</title>
              <displayCode>/Spin-off companies</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456213</code>
              <title>Product innovation</title>
              <displayCode>/Product innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43454395</code>
              <title>Marketing strategy</title>
              <displayCode>/Marketing strategy</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453822</code>
              <title>Investment readiness</title>
              <displayCode>/Investment readiness</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43452043</code>
              <title>Feasibility analysis</title>
              <displayCode>/Feasibility analysis</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458031</code>
              <title>Sustainable innovation</title>
              <displayCode>/Sustainable innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450041</code>
              <title>Business support services</title>
              <displayCode>/Business support services</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458163</code>
              <title>Technological innovation</title>
              <displayCode>/Technological innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43457365</code>
              <title>SME support</title>
              <displayCode>/SME support</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456414</code>
              <title>Public sector innovation</title>
              <displayCode>/Public sector innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456186</code>
              <title>Private investment</title>
              <displayCode>/Private investment</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453576</code>
              <title>Innovation management</title>
              <displayCode>/Innovation management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450521</code>
              <title>Company valuation</title>
              <displayCode>/Company valuation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43452100</code>
              <title>Financial &amp; Investment management</title>
              <displayCode>/Financial &amp; Investment management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43451181</code>
              <title>Due diligence</title>
              <displayCode>/Due diligence</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43451088</code>
              <title>Disruptive innovation</title>
              <displayCode>/Disruptive innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458202</code>
              <title>Technology management</title>
              <displayCode>/Technology management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450026</code>
              <title>Business management</title>
              <displayCode>/Business management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450017</code>
              <title>Business development</title>
              <displayCode>/Business development</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458661</code>
              <title>Venture capital</title>
              <displayCode>/Venture capital</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450014</code>
              <title>Business coaching and mentoring</title>
              <displayCode>/Business coaching and mentoring</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456756</code>
              <title>Risk management</title>
              <displayCode>/Risk management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453837</code>
              <title>IPR management</title>
              <displayCode>/IPR management</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1040766</rcn>
        <id>190129097_PSHORIZON</id>
        <title>Periodic Reporting for period 2 - CD20CARNAPT (iTANK: a nuniversal technology to boost the efficacy of CAR T cell therapies by inducing dual mode-of-actio)</title>
        <description>periodic</description>
        <teaser>Chimeric antigen receptor CAR-T cell therapy has been approved as a second/third-line treatment for patients with chemotherapy-resistant B cell tumors. So far, four therapies with CD19 CAR-T cells have been approved in the EU for B-cell leukemia and lymphoma (Yescarta...</teaser>
        <sourceUpdateDate>2025-02-17 20:05:29</sourceUpdateDate>
        <contentUpdateDate>2025-02-17 20:05:29</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1257201</rcn>
        <id>190129097_621FF602A4B9963BCEFB6E02C120DDD8_IPRHORIZON</id>
        <title>T-CELL IMMUNOTHERAPY</title>
        <details>
          <iprAwarded>EP3512537A1</iprAwarded>
          <iprNumber>P3512537A1</iprNumber>
          <iprDate>2023-11-01</iprDate>
          <iprPrefix>E</iprPrefix>
        </details>
        <sourceUpdateDate>2025-02-17 20:05:29</sourceUpdateDate>
        <contentUpdateDate>2025-02-17 20:05:29</contentUpdateDate>
        <relations>
          <associations>
            <organization source="corda" type="isRegisteredBy">
              <availableLanguages>en</availableLanguages>
              <rcn>1978148</rcn>
              <id>890218568</id>
              <vatNumber>SE556966495501</vatNumber>
              <legalName>ELICERA THERAPEUTICS AB</legalName>
              <address>
                <street>BOX 5243</street>
                <city>GOTEBORG</city>
                <postalCode>402 24</postalCode>
                <country>SE</country>
                <geolocation>57.6487986,11.719643465644351</geolocation>
              </address>
              <relations>
                <categories>
                  <category classification="organizationActivityType" type="relatedOrganizationActivityType">
                    <language>en</language>
                    <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
                    <code>/PRC</code>
                    <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
                    <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
                  </category>
                </categories>
                <regions>
                  <region type="relatedNutsCode">
                    <name>Västra Götalands län</name>
                    <rcn>473440450</rcn>
                    <nutsCode>SE232</nutsCode>
                    <parents>
                      <region>
                        <name>Västsverige</name>
                        <rcn>473440488</rcn>
                        <nutsCode>SE23</nutsCode>
                        <parents>
                          <region>
                            <name>Södra Sverige</name>
                            <rcn>473442856</rcn>
                            <nutsCode>SE2</nutsCode>
                            <parents>
                              <region>
                                <name>Sweden</name>
                                <rcn>473598504</rcn>
                                <nutsCode>SE</nutsCode>
                                <euCode>SE</euCode>
                                <isoCode>SE</isoCode>
                              </region>
                            </parents>
                          </region>
                        </parents>
                      </region>
                    </parents>
                  </region>
                  <region type="relatedRegion">
                    <name>Sweden</name>
                    <rcn>473598504</rcn>
                    <nutsCode>SE</nutsCode>
                    <euCode>SE</euCode>
                    <isoCode>SE</isoCode>
                  </region>
                </regions>
              </relations>
            </organization>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/ipr</code>
              <title>Intellectual Property Rights</title>
              <description>Result: Intellectual property rights linked to the results of EU funded research (FP7 onwards)</description>
              <displayCode>/Intellectual Property Rights</displayCode>
            </category>
            <category classification="iprType" type="isRegisteredAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/OTHER</code>
              <title>Other</title>
              <displayCode>/Other</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1188977</rcn>
        <id>190129097_8617_PUBLIHORIZON</id>
        <title>CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers</title>
        <details>
          <authors>Chuan Jin, Jing Ma, Mohanraj Ramachandran, Di Yu &amp; Magnus Essand</authors>
          <journalNumber></journalNumber>
          <journalTitle>Nature Biomedical Engineering</journalTitle>
          <publishedPages></publishedPages>
          <publishedYear>2022</publishedYear>
          <publisher>Nature publishing group</publisher>
        </details>
        <identifiers>
          <issn>2157-846X</issn>
          <doi>10.1038/s41551-022-00875-5</doi>
        </identifiers>
        <sourceUpdateDate>2024-01-06 00:36:27</sourceUpdateDate>
        <contentUpdateDate>2024-11-15 09:21:01</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode>/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PEER_REVIEWED_ARTICLE</code>
              <title>Peer reviewed articles</title>
              <displayCode>/Peer reviewed articles</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/155/643</code>
        <title>immunotherapy</title>
        <displayCode>/medical and health sciences/basic medicine/immunology/immunotherapy</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/37/163</code>
        <title>cells technologies</title>
        <displayCode>/medical and health sciences/medical biotechnology/cells technologies</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-EIC-ACC-BF</code>
        <title>HORIZON EIC Accelerator Blended Finance</title>
        <description>HORIZON EIC Accelerator Blended Finance</description>
        <displayCode>/HORIZON EIC Accelerator Blended Finance</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>